About Checkpoint Therapeutics (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CKPT
CUSIPN/A
Phone781-652-4500
Debt
Debt-to-Equity RatioN/A
Current Ratio3.36%
Quick Ratio3.36%
Price-To-Earnings
Trailing P/E Ratio-3.88
Forward P/E Ratio-4.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.73 million
Price / Sales71.79
Cash FlowN/A
Price / CashN/A
Book Value$0.59 per share
Price / Book6.58
Profitability
EPS (Most Recent Fiscal Year)($1.00)
Net Income$-22,670,000.00
Net Margins-1,316.72%
Return on Equity-102.39%
Return on Assets-83.05%
Miscellaneous
Employees6
Outstanding Shares32,010,000
Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions
What is Checkpoint Therapeutics' stock symbol?
Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."
How were Checkpoint Therapeutics' earnings last quarter?
Checkpoint Therapeutics (NASDAQ:CKPT) announced its quarterly earnings data on Friday, March, 16th. The company reported ($0.26) EPS for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.01. The business earned $0.33 million during the quarter, compared to analyst estimates of $0.35 million. Checkpoint Therapeutics had a negative net margin of 1,316.72% and a negative return on equity of 102.39%. View Checkpoint Therapeutics' Earnings History.
What price target have analysts set for CKPT?
1 Wall Street analysts have issued 1-year target prices for Checkpoint Therapeutics' shares. Their predictions range from $11.00 to $11.00. On average, they expect Checkpoint Therapeutics' stock price to reach $11.00 in the next year. View Analyst Ratings for Checkpoint Therapeutics.
Who are some of Checkpoint Therapeutics' key competitors?
Some companies that are related to Checkpoint Therapeutics include StemlineTherapeutics (STML), Akebia Therapeutics (AKBA), Insys Therapeutics (INSY), Progenics Pharmaceuticals (PGNX), Achillion Pharmaceuticals (ACHN), ObsEva (OBSV), CannTrust (CNTTF), Innate Pharma (IPHYF), MediciNova (MNOV), Zealand Pharma (ZEAL), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE) and Synergy Pharmaceuticals (SGYP).
Who are Checkpoint Therapeutics' key executives?
Checkpoint Therapeutics' management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman (Age 52)
- Mr. James F. Oliviero III, CFA, Chief Exec. Officer and Pres (Age 42)
- Mr. William Garrett Gray, Principal Financial Officer and VP of Fin. & Accounting (Age 31)
- Ms. Robyn M. Hunter, Corp. Sec.
Has Checkpoint Therapeutics been receiving favorable news coverage?
News headlines about CKPT stock have been trending somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Checkpoint Therapeutics earned a coverage optimism score of 0.20 on Accern's scale. They also gave media headlines about the company an impact score of 44.92 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Checkpoint Therapeutics?
Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Checkpoint Therapeutics' stock price today?
One share of CKPT stock can currently be purchased for approximately $3.88.
How big of a company is Checkpoint Therapeutics?
Checkpoint Therapeutics has a market capitalization of $131.90 million and generates $1.73 million in revenue each year. The company earns $-22,670,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Checkpoint Therapeutics employs 6 workers across the globe.
How can I contact Checkpoint Therapeutics?
Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected].com.
MarketBeat Community Rating for Checkpoint Therapeutics (CKPT)
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Checkpoint Therapeutics in the last 12 months. Their average twelve-month price target is $11.00, suggesting that the stock has a possible upside of 183.51%. The high price target for CKPT is $11.00 and the low price target for CKPT is $11.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.00 | $11.00 | $11.00 | N/A |
| Price Target Upside: | 183.51% upside | 138.61% upside | 138.61% upside | N/A |
Checkpoint Therapeutics (NASDAQ:CKPT) Consensus Price Target History
Checkpoint Therapeutics (NASDAQ:CKPT) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Checkpoint Therapeutics (NASDAQ:CKPT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Checkpoint Therapeutics (NASDAQ CKPT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.70%
Institutional Ownership Percentage: 0.56%
Checkpoint Therapeutics (NASDAQ CKPT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Checkpoint Therapeutics (NASDAQ CKPT) News Headlines
| Source: |
|
Checkpoint Therapeutics (NASDAQ:CKPT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Checkpoint Therapeutics (NASDAQ CKPT) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
